Kansas Senate Bill SB43

Kansas 2023-2024 Regular Session

• Introduced: 1/18/23
• Refer: 1/19/23
• Failed: 4/30/24

Caption

Making and concerning appropriations for the university of Kansas medical center for fiscal years 2023, 2024 and 2025 for conducting certain clinical trials at the midwest stem cell therapy center.

Impact

The financial provisions outlined in SB43 facilitate ongoing research in stem cell therapy, which may advance treatment options for respiratory conditions exacerbated by COVID-19. By earmarking substantial funds for the Midwest Stem Cell Therapy Center, the bill underscores the importance of innovative medical research and its potential benefits for public health. Should the clinical trials yield positive outcomes, they could significantly impact treatment protocols and health regulations associated with infectious diseases.

Summary

Senate Bill 43 concerns appropriations for the University of Kansas Medical Center, specifically designated for conducting clinical trials related to the treatment of COVID-19 and other respiratory diseases through the use of stem cells. For the fiscal years ending June 30, 2023, 2024, and 2025, the bill allocates a maximum of $500,000 for these trials to be conducted at the Midwest Stem Cell Therapy Center. The funding is structured in a way that allows for reappropriation of unencumbered balances in subsequent years, ensuring continuous support of the trials if needed.

Contention

While the bill aims to foster healthcare advances, there may be underlying concerns regarding the ethical implications of stem cell research and the allocation of state resources toward such projects. Opponents of similar funding measures often raise points about the efficacy and ethical practices within clinical trials involving stem cells. As discussions progress, it may become necessary to address these ethical concerns to ensure public confidence in the initiatives supported by state appropriations.